Trastuzumab, Herceptin, should remain the standard of care for HER2-positive breast cancer, says a Mayo Clinic researcher, after analysis of more than 8,000 women with the cancer. These women participated in the world's largest study of two treatments for HER2-positive breast cancer. This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard ...
Read MoreYou have just read an article categorized health
titled Standard Care for HER2-Positive Breast Cancer: Trastuzumab.
Written by:
editor - Tuesday, September 30, 2014
There are currently no comments for "Standard Care for HER2-Positive Breast Cancer: Trastuzumab"
Post a Comment